| Stage | LLY | % of rev | HRMY | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $24.4B | 100.00% | $261M | 100.00% | LLY ×93.37 |
| Gross profit | $20.5B | 83.88% | $198M | 75.81% | LLY +8.1pp |
| Operating income | $8.6B | 35.28% | $89M | 34.18% | LLY +1.1pp |
| Pre-tax income | $8.4B | 34.46% | $93M | 35.70% | HRMY +1.2pp |
| Net income | $6.5B | 26.44% | $75M | 28.87% | HRMY +2.4pp |
| Stage | LLY | HRMY | Gap · A − B |
|---|---|---|---|
| Revenue | $24.4B100.00% | $261M100.00% | LLY ×93.37 |
| Gross profit | 83.88%$20.5B | 75.81%$198M | LLY +8.1pp |
| Operating income | 35.28%$8.6B | 34.18%$89M | LLY +1.1pp |
| Pre-tax income | 34.46%$8.4B | 35.70%$93M | HRMY +1.2pp |
| Net income |
| 26.44%$6.5B |
| 28.87%$75M |
| HRMY +2.4pp |
LLY 10-KFeb 12 '26
“In 2025, 2024, and 2023, three wholesale distributors in the U.S.—McKesson Corporation, Cencora, Inc., and Cardinal Health, Inc.—each accounted for a significant percentage of our consolidated revenue.”
HRMY 10-KFeb 24 '26
“Cardinal Health, Inc. is our third-party logistics provider and manages reverse distribution, pharmaceutical returns and product recall, if needed.”